BMS, Breyanzi, CAR - T Cell therapy, CAR T-Cell, CART therapy, USFDA
Breyanzi – New CAR T-Cell therapy from BMS
July 2021: Breyanzi (Lisocabtagene maraleucel; liso-cel), a novel CD19-directed chimeric antigen receptor (CAR) T cell treatment developed by Bristol Myers Squibb (BMS), has been approved by the US Food and Drug Administration (US..
CAR - T Cell therapy, CART therapy, China CAR T Cell therapy, Leukemia, T Cell Leukemia
CAR T-Cell therapy for T-cell acute lymphoblastic leukaemia (T-ALL)
June 2021 : As per our resources, a hospital in China has developed CAR T-Cell therapy for T-cell acute lymphoblastic leukaemia (T-ALL). The expressing protein in this case is CD7. 5 patients have been tested with the therapy, and..
Acalabrutunib, Avelumab, CART therapy, Dabrafanib, Kymriah, Latest drugs, Midostaurin, Niraparib, Pembrolizumab, Tecartus, Tisagenlecleucel, Trametinib, USFDA
Latest drugs in the treatment of cancer
July 2021: Check out the latest drugs in the treatment of cancer. Every year, after examining the trials and other important factors, the USFDA approves drugs, and thus cancer patients can now believe that a cure is very near. ..